# Opticyte

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/opticyte

- Industry: Medical Devices & Equipment
- Headquarters: Seattle, US
- Website: www.opticyte.com
- Total disclosed funding: $1.7M
- Latest round: Seed (Nov 1, 2020)
- Investors on record: 2

## About

Opticyte, Inc. is a medical technology company dedicated to improving patient outcomes through innovative monitoring solutions. Their flagship product, the VitalO2 device, accurately measures cellular oxygen levels to aid in critical medical diagnoses.Founded in 2016, Opticyte, Inc. is based in Seattle, US, focusing on advanced medical technologies. The company was established by Kenneth Schenkman. Opticyte targets hospitals and healthcare facilities in the United States, having recently raised USD 4.6 mn in a funding round on January 12, 2021, bringing their total funding to USD 4.6 mn across three deals.Opticyte specializes in advanced medical technologies, focusing primarily on its flagship product, the VitalO2 device. This innovative tool is designed to accurately monitor cellular oxygen levels in patients, addressing critical needs in the early detection and treatment of conditions such as sepsis, trauma, and respiratory failure. Unlike traditional pulse oximeters, which have demonstrated significant racial bias in diagnosing blood oxygen levels, the VitalO2 employs sophisticated machine learning algorithms trained on a diverse dataset to ensure reliable results across all skin tones. The company's primary target market includes hospitals and healthcare facilities within the United States, where the need for improved diagnostic accuracy is paramount, particularly in emergency and critical care settings.Opticyte's revenue model is primarily structured around direct sales of the VitalO2 device to healthcare institutions and medical facilities. The company engages in B2B transactions, supplying its technology to hospitals that are keen to enhance their diagnostic capabilities and improve patient outcomes. Revenue is generated through one-time equipment sales and may also include service agreements or educational partnerships that support the integration of the VitalO2 into existing clinical workflows. The company has secured substantial funding, including over USD 4 mn from the National Institutes of Health, which underscores its credibility and potential for growth within the healthcare sector.Opticyte plans to expand its product offerings with upcoming enhancements to the VitalO2 device, although specific release dates have not been disclosed. The company aims to penetrate new markets, specifically targeting additional healthcare facilities across the United States by 2023. The recent funding of USD 4.6 mn will be utilized to support the development of these new products and to facilitate market expansion efforts.

## Funding rounds

- Seed, Nov 1, 2020, $1.7M — SWAN Venture Fund, StarFish Product Engineering Inc.

## Investors

- SWAN Venture Fund (https://capitalatlas.ai/funds/swan-venture-fund) — Seed
- StarFish Product Engineering Inc. — Seed